Verona Pharma Share Discussion Threads

[haff1] 30/10/2015 08:54

Ive been here for years and this constant jam tomorrow is wearing thin

[ilovetowin] 30/10/2015 08:34

Watch out. Looks like forward selling of placingExpect RNS within 7 days and the drop into low 2's will be explained

[aimshares] 30/10/2015 08:22

I no funding is coming ,I just hope they don't dilute us at 2.2p like last time ,I will be very disappointed and angry .

[meijiman] 29/10/2015 16:48

Don't need any more good news then! MMs just hitting anything where there does not seem to be underlying buying interest.

[corbine] 14/10/2015 09:42

timbo-i agree thats a strong possibility, those 2 drugs salbutomol (Ventolin,(the rescue drug) and ipratropium bromide? are the standard benchmark use combined in nebbed useage currently for copd users with severe copd and also same is used when admitted to er with exacerbations.
say its a marked improvement, cant u also see its a double win win for vrp 554 and shows it can be stand alone improvement as well as imrpovement with the add on of mixed with either or both current mainstream nebbed drugs, then couldnt vrp partner so maintain control as well as have majors trying to buy them out completely?
(cant recall delivery via nebbs whilst in exacerbation mode and user is on 10-16 litres 02 same time via venturi? mask as well? esp in er settings.
corbs :-)

[aimshares] 14/10/2015 09:38

Got it so the may be the T/O route.

[timbo003] 14/10/2015 09:28

>>>AIM shares

Nope, I don't think that fate awaits them. Given that the current trend seems to be to go for all possible combinations and permutations for inhalation therapy (look at GSK's recent launches and development pipeline around their new LABA, SABA and AI) then I suspect the desire to combine RPL554 with these established compounds in proprietary devices will seem quite compelling to big pharma. The easiest way to do that would be to buy Verona.

[aimshares] 14/10/2015 09:17

timbo ( , then I suspect it's bye bye Verona as an independent AIM quoted plc.)Do you mean they will go private ?

[timbo003] 14/10/2015 08:20

The combo Study is due to complete mid-way Q3 (see timeline in header)

Study details from Clintrials.gov are here:



They are comparing it with both Salbutamol and with Ipratropium

They will need more funds before completion, but if they show a synergistic effect (or even just an additive effect) with either of these two, then I suspect it's bye bye Verona as an independent AIM quoted plc.

[thebossman] 14/10/2015 07:15

VRP starts 11a study...

[wageslave] 09/10/2015 12:55

Still has an outstanding funding requirement in 2016 to progress drug trials as per the analysts report. This may be the reason for the uncertainty and share price weakness.

[kingofallbaxters] 09/10/2015 11:15

Hope theres no more good news, or we could all end up bankrupt!

[meijiman] 09/10/2015 09:25

Difficult to figure out the share price moves here.

[thebossman] 08/10/2015 12:15

Today's Rns

[corbine] 03/10/2015 09:53

will do this weekend when rugby not on-thanks for the links timbo

[timbo003] 03/10/2015 07:41

>>>>corbs

Take a look at the Hardman initiation report (May 18th), link in header (and below)



It discusses P38 inhibitors along with other emerging treatments (both inhaled and oral).

I suspect being anti inflamatory, P38 inhibitors will be more suitable for maintenance therapy rather than exacerbations.

Just looking around, it seems like GSK, Pfizer and Astra are all looking into the area (inhaled and oral dosage forms), for example, see links below which document some of Pfizer's endeavours:

[corbine] 02/10/2015 18:34

me too vas-thought worth putting it up as i know how well u guys can trawl and access research gubbins :-)
have agood weekend all
corbs:-)

[vasilis] 02/10/2015 17:05

Thanks for that link Corbs.

All we appear to know from what that article says are the effects on 30 healthy volunteers of a single 1200mcgs dose of AZD7624. Let's see what happens when actual COPD patients are dosed as stated at the end of the article -

'Patel and other AstraZeneca officials are currently recruiting participants for a phase IIa study to investigate the efficacy and safety of AZD7624 in COPD patients who are on standard maintenance therapy.'

I can't find anything about the composition of the AZD7624 molecule itself or what actually constitutes a 'single inhaled dose'.

[peawacks] 02/10/2015 12:25

For information.

[corbine] 02/10/2015 10:59

thanks guys-saw this also -worth keeping an eye on what else is out there in various stages of design? comments welcome timbo-vas etc...

[vasilis] 02/10/2015 10:38

As well as the article in Fierce Biotech - see link above provided by bewise2 - there is this interesting article in Chemistry World -

Note especially the last section 'try before you buy' and the comments made by JAK. The conference later this month is clearly a very opportune time for VRP to publicise the latest results for RPL554.

[bewise2] 01/10/2015 23:25

www.fiercebiotech.com/story/verona-sets-sights-phiib-after-copd-drug-comes-through-early-trial/2015-10-01

[vasilis] 01/10/2015 16:56

First opportunity for JAK to publicly update the COPD research community is on the 19th October. He is speaking on the first day with a good slot at 11am -


Interesting that he is followed by Ewan Walters of Teva UK speaking on 'optimising treatment for COPD - new strategies for combination therapy'.